Serina Therapeutics, Inc.

Serina Therapeutics, Inc.

SER·NYSE

$5.00

+0.0000%
HealthcareBiotechnology

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

At a Glance

Live Snapshot
Market Cap$51.25M
EPS-0.6445
P/E Ratio-2.39
Earnings Date11/11/2025

ser

Total Equity

Last Annual Value

508.00K

3-Year CAGR

26%

5-Year CAGR

-28%

10-Year CAGR

7%

Serina Therapeutics, Inc.

Serina Therapeutics, Inc. Competitors Analysis of Total Equity

SER · NYSE
CompanyTotal Equity
CAGR 3Y
CAGR 5Y
CAGR 10Y
508.00K
-54.4%N/AN/A 
-9.51M
N/AN/AN/A
17.75M
60.3%49.8%N/A
-10.37M
N/AN/AN/A
62.18M
239.6%-22.7%-2.8%
-292.93M
N/AN/AN/A
25.65M
-27.4%-15.7%N/A
5.91M
19.8%N/AN/A
Serina Therapeutics, Inc.

Serina Therapeutics, Inc. Fair Value Envelope

SER · NYSE

Our analysis suggests that SER has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5, this represents a potential HIDDEN relative to our calculated worth for Serina Therapeutics, Inc..

Intrinsic Value
Current Price: $5